Interacciones de Bexaroteno

Acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids . (etiqueta de Acitretina, Contraindicaciones)

Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN [ see Drug Interactions (7) ]. (etiqueta de Bexaroteno, Advertencias y precauciones)

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (etiqueta de Minociclina, Advertencias y precauciones)

Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (etiqueta de Tetraciclina, Advertencias)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (etiqueta de Tretinoína, Contraindicaciones)

Patients with CTCL who have risk factors for pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity) may be at greater risk for pancreatitis associated with TARGRETIN… (etiqueta de Bexaroteno, Advertencias y precauciones)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (etiqueta de Cloruro de calcio, Interacciones medicamentosas)

Patients with elevated vitamin A levels may be at increased risk. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Patients with elevated vitamin A levels may be at increased risk. (etiqueta de Ivacaftor, Advertencias y precauciones)

Monitor and replace thyroid hormone if needed. (etiqueta de Bexaroteno, Advertencias y precauciones)

Monitor and replace thyroid hormone if needed. (etiqueta de Bexaroteno, Advertencias y precauciones)

Monitor and replace thyroid hormone if needed. (etiqueta de Bexaroteno, Advertencias y precauciones)

Monitor and replace thyroid hormone if needed. (etiqueta de Bexaroteno, Advertencias y precauciones)

Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (etiqueta de Metotrexato, Interacciones medicamentosas)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (etiqueta de Orlistat, Interacciones medicamentosas)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Monitor and replace thyroid hormone if needed. (etiqueta de Bexaroteno, Advertencias y precauciones)

Monitor and replace thyroid hormone if needed. (etiqueta de Bexaroteno, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (etiqueta de Bexaroteno, Advertencias y precauciones)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (etiqueta de Bexaroteno, Advertencias y precauciones)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Vitamin A Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. (etiqueta de Fluconazol, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (etiqueta de Gluconato de calcio, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (etiqueta de Bexaroteno, Interacciones medicamentosas)